Singapore-based biotechnology company Nuevocor has secured $45m in a Series B financing round to advance its novel mechanobiology-centred therapy for cardiomyopathy.
The funding round was co-led by Kurma Partners and Angelini Ventures.
Other participants include existing investors Boehringer Ingelheim Venture Fund, ClavystBio, EDBI, Highlight Capital, and SEEDS Capital.
Kurma Partners’ partner Amanda Gett-Chaperot said: “Nuevocor is providing new hope to a significant population of cardiovascular patients who today lack treatment options by directly targeting the underlying causes of disease.
“The burden of cardiomyopathies is large, and Kurma is excited to join Nuevocor, investing from our new Biofund IV to create meaningful value through the treatment of these important diseases.”
Nuevocor CEO and co-founder Yann Chong Tan said: “We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors.
“The continued strong support from insiders and the addition of new investors will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic. This is an example of how Singapore is bringing transformative innovation to the rest of the world.”
Nuevocor will use the funds for a first-in-human Phase 1/2 clinical trial of NVC-001, targeting patients with LMNA-related dilated cardiomyopathy (LMNA DCM), in Europe and the US.
NVC-001 is an AAV-based gene therapy candidate designed to treat LMNA DCM by restoring nuclear envelope integrity and reducing forces on the nucleus.
LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene, weakening the heart muscle, and often progressing to end-stage heart failure.
Angelini Ventures managing director Elia Stupka said: “Our investment in Nuevocor marks a strategic expansion for Angelini Ventures – into cardiovascular disease, gene therapy, and the Singapore biotech ecosystem.
“We are excited by Nuevocor’s novel approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes. This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens.
“We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company grows globally, including into Europe.”
